Addressing Bias in Responder Analysis of Patient-Reported Outcomes

Joseph C. Cappelleri1 · Richard Chambers2

Received: 15 November 2020 / Accepted: 20 April 2021 / Published online: 27 May 2021
© The Author(s) 2021

Abstract

Introduction Quantitative patient-reported outcome (PRO) measures ideally are analyzed on their original scales and responder analyses are used to aid the interpretation of those primary analyses. As stated in the FDA PRO Guidance for Medical Product Development (2009), one way to lend meaning and interpretation to such a PRO measure is to dichotomize between values where within-patient changes are considered clinically important and those that are not. But even a PRO scale with a cutoff score that discriminates well between responder and non-responders is fraught with some misclassification.

Methods Using estimates of sensitivity and specificity on classification of responder status from a PRO instrument, formulas are provided to correct for such responder misclassification under the assumption of no treatment misclassification. Two case studies from sexual medicine illustrate the methodology.

Results Adjustment formulas on cell counts for responder misclassification are a direct extension of correction formulas for misclassification on disease from a two-way cross-classification table of disease (yes, no) and exposure (yes, no). Unadjusted and adjusted estimates of treatment effect are compared in terms of odds ratio, response ratio, and response difference. In the two case studies, there was considerable underestimation of treatment effect.

Discussion and conclusions The methodology can be applied to different therapeutic areas. Limitations of the methodology, such as when adjusted cell estimates become negative, are highlighted. The role of anchor-based methodology is discussed for obtaining estimates of sensitivity and specificity on responder classification. Correction for treatment effect bias from misclassification of responder status on PRO measures can lead to more trustworthy interpretation and effective decision-making.

Clinicaltrials.gov: NCT00343200

Keywords Information bias · Patient-reported outcomes · Responder analysis · Misclassification · Measurement error · Treatment effect

Introduction

Ideally, a clinical trial should be able to demonstrate not only a statistically significant improvement in a clinical endpoint, but also that the magnitude of the effect is clinically relevant. A patient-reported outcome (PRO) measure, one type of clinical endpoint, is any report on the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else [1]. Unlike well-established clinical measurements such as survival and blood pressure, which are generally understood and can be measured directly, the scoring of latent (unobserved) concepts captured by a PRO measure (and health measurement scales in general) may be unfamiliar to many healthcare professionals and patients [2]. Researchers may lack the sufficient data, experience, or clinical understanding to interpret the relevance or meaningfulness of scores or change in scores on a self-reported rating scale.

Quantitative PRO measures ideally are analyzed on their original metric and responder analyses are used to augment the interpretation of those primary analyses. One way to lend meaning and interpretation to a quantitative PRO measure is to dichotomize between values where within-patient changes are considered clinically important (“responders”) and those that are not [3, 4]. This type of responder analysis

1 Global Biometrics and Data Management, Pfizer Inc., Groton, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA
2 Global Biometrics and Data Management, Pfizer Inc., Collegeville, PA, USA
is in common use in clinical trials and has been described in regulatory documents [1, 5], especially where “soft” clinical endpoints such as PRO measures are used. For instance, interpretation can be enriched by establishing meaningful change in PRO measures at the individual level (i.e., defining a responder) and calculating and comparing the proportion of response as defined by this predetermined clinically important change between the treatment groups [1]. The procedure is useful because between-group differences in responder proportions or percentages may be understood more intuitively than a difference in mean scores from rating scales.

Consider, for instance, a PRO measure like self-reported pain measured with a 11-point pain intensity numerical rating scale, where 0 = no pain and 10 = worst possible pain, over the past 24 h [6]. One proposed approach to enrich its interpretation, and that of other patient-reported measures, is to conduct a responder analysis where a quantitative measure is dichotomized into "responders" and "non-responders" [7, 8]. The outcome can be defined as a score on the pain scale at a postbaseline visit or as change from baseline to the postbaseline visit. In this type of responder analysis, the original metric of pain can be dichotomized at a cutoff or threshold value one side of which a subject is considered a "responder" (e.g., at least 30% reduction or two-point absolute reduction in pain from baseline to end of study) and the other side of which a subject is considered to be a “non-responder” [6].

Anchor-based methods, which examine the association between the targeted concept of the PRO instrument and the concept measured by the anchor (or anchors), can provide the primary empirical evidence to estimate a cutoff or threshold score for the responder definition of the targeted PRO; distribution-based approaches, which rely solely on the distribution of the data using descriptive measures (such as means, standard deviations, reliability of the PRO measure), can serve as an adjunct method to determine a responder cutoff of the PRO measure [1, 2, 4, 9]. But classification of responder status, be it based on anchor-based or distribution-based approaches, is not measured perfectly. Even a PRO scale with a cutoff score that discriminates well between responders and non-responders is fraught with some misclassifications: Some individuals classified as responders (based on the cutoff or threshold score on the PRO measure) may in fact be non-responders; some individuals classified as non-responder may, in fact, be responders. Yet there has been no attempt in research to adjust for responder misclassification on a PRO measure.

In this article, formulas are provided to correct for responder misclassification under the assumption of no treatment misclassification in a two-by-two contingency table. A general framework is provided to illustrate how responder misclassification affects measures of treatment effect (responder ratio, responder difference, odds ratio). Estimates of treatment effect are compared between unadjusted and adjusted estimates of treatment effect using two cases studies from sexual medicine to illustrate the methodology. Limitations of the methodology are discussed. The article concludes with points to consider and possible extensions on responder analysis and misclassification.

### Methods: Correction Formulas for Responder Misclassification

Formulas exist for correcting for misclassification on disease or exposure, or both, for a two-way cross-classification table of disease status (yes, no) and exposure status (yes, no) [10, 11]. But these formulas have not been applied in the context of responder analysis in general and for PRO measures in particular. In the current exposition, no misclassification of treatment is assumed, a reasonable assumption in experimental and quasi-experimental studies where the investigator directs treatment allocation (be it randomly or non-randomly). The formulas with misclassification on disease only (and no misclassification on treatment) can be applied directly and modified by replacing disease (yes, no) with responder status (yes, no).

Suppose that a validation study is undertaken on responder status of the targeted patient-reported outcome of interest. Assume that data consist of observed responder status (yes, no) by self-report, and there was a way to know with certainty each subject’s true responder status. In this case, the data could be laid out as a two-by-two contingency table shown in Table 1, called a validation table. Along the interior columns, subjects are classified according to their true responder status, while along the interior, row subjects are classified as responder or non-responder according to the numerical threshold or cutoff chosen on the PRO measure of interest.

Table 1 contains elements of diagnostic statistics that are used to correct measures for misclassification. In particular, the sensitivity of response is the number that are true responders who are classified correctly as such, divided by the number of true responders; the specificity of response

| True responder | True non-responder |
|----------------|--------------------|
| Classified as responder | E | F |
| Classified as non-responder | G | H |
| Total | E + G | F + H |

Note Letters (E, F, G, H) represent counts of subjects, sensitivity = E/(E + G), and specificity = H/(F + H).
is the number that are true non-responders who are classified correctly as such, divided by the number of true non-responders.

Table 2 provides the equations for calculating expected observed data from the true data given sensitivity and specificity, adapted from other sources based on disease misclassification [10, 11]. The equations in Table 2 can then be algebraically rearranged to solve, in reverse, for the true or corrected cell counts (A, B, C, D) as a function of the observed cell counts (a, b, c, d) and sensitivity and specificity for responder classification under the assumption of differential or non-differential misclassification with respect to treatment (Table 3). In this case, non-differential misclassification exists when the pair of sensitivities for responder classification, one for experimental treatment and the other for control treatment, are equal and, separately, when the pair of specificities for responder classification also do not differ between the two treatments; otherwise, when either pair or both pairs are different between treatments, differential misclassification exists.

Again, instead of the outcome being disease status, as is commonly considered, the outcome now becomes responder status; typically, the other variable is also called the exposure variable that is referred to as the treatment variable here. As noted, responder status and treatment type are each taken to have two levels or categories.

Effect of Non-differential Responder Misclassification on Estimates of Treatment Effect

In Table 4 data are presented for a hypothetical study with 2,000 subjects, half on the experimental treatment and the other half on the control treatment. The true association

Table 2 Equations for calculating expected observed data (when there is responder misclassification only): based on true data

| Outcome | Truth | Expected observed |
|---------|-------|-------------------|
|         | Treatment | Treatment |
|         | T1 | T0 | T1 | T0 |
| R+ | A | B | \(a = A(SE_{T1}) + C(1-SP_{T1})\) | \(b = B(SE_{T0}) + D(1-SP_{T0})\) |
| R− | C | D | \(c = C(SP_{T1}) + A(1-SE_{T1})\) | \(d = D(SP_{T0}) + B(1-SE_{T0})\) |
| Total | A+C | B+D | \(a+c\) | \(b+d\) |

Table 3 Equations for correcting observed data given sensitivity and specificity for responder misclassification (no treatment misclassification)

| Outcome | Treatment | Expected truth |
|---------|----------|---------------|
|         | Treatment | Treatment |
|         | T1 | T0 | T1 | T0 |
| R+ | a | b | \(A = \frac{[a(SP_{T1})-c(1-SP_{T1})]}{(SE_{T1} + SP_{T1}-1)}\) | \(B = \frac{[b(SP_{T0})-d(1-SP_{T0})]}{(SET0 + SP_{T0}-1)}\) |
| R− | c | d | \(C = \frac{[c(SE_{T1})-a(1-SE_{T1})]}{(SE_{T1} + SP_{T1}-1)}\) | \(D = \frac{[d(SE_{T0})-b(1-SE_{T0})]}{(SET0 + SP_{T0}-1)}\) |
| Total | a+c | b+d | A+C | B+D |

Note As with Table 1, T1 and T0 denote experimental treatment and control treatments, respectively, and are measured perfectly (no misclassification of treatment); R+ denotes responder, R− denotes non-responder; \(SE_{T1}\) and \(SE_{T0}\) are sensitivity of responder status in T1 and T0, respectively (which permit for differential misclassification); \(SP_{T1}\) and \(SP_{T0}\) are specificity of responder status in T1 and T0, respectively (which permit for differential misclassification). Tables 2 and 3 also allow for non-differential misclassification where, by definition, the mechanism of misclassification assumes that sensitivities and, separately, the specificities for misclassifying responder status do not differ by treatment (i.e., \(SE_{T1} = SE_{T0} = SE\) and \(SP_{T1} = SP_{T0} = SP\)) and the denominator therefore reduces to \(SE + SP - 1\).

Table 4 Hypothetical true association between treatment and response

| Response status | Treatment status |
|----------------|-----------------|
| Responder (R+) | Experimental | Control |
| Non-responder (R−) | A = 800 | B = 400 |
| Total | 1000 | 1000 |
| Response rate | 0.8 | 0.4 |
| Response difference | 0.4 | |
| Response ratio | 2.0 | |
| Odds ratio | 6.0 | |
between treatment and response has a response ratio of 2,
a response difference of 0.4, and an odds ratio of 6. With
these data, Figs. 1, 2 and 3 show the relation of sensitiv-
ity and specificity with the expected observed response
ratio (Fig. 1), response difference (Fig. 2), and odds ratio
(Fig. 3) under the assumption of non-differential responder
misclassification and no treatment misclassification. Alter-
native scenarios on treatment response rates and their con-
sequences can be produced by directly applying the same
formulas from Table 2 and, without loss of generality,
would show the same general patterns as those depicted in
Figs. 1, 2 and 3 (when the experimental treatment response
exceeds the control treatment response).

When sensitivity is held at 100% and specificity ranges
from 50 to 100%, there is an inverse relation between
specificity and bias in the response ratio; as the specificity
increases, the bias decreases (Fig. 1a). Even a specificity of
95% will yield a response ratio of 1.88, close to the truth
(2.0) though not completely unbiased. Conversely, when
specificity is held at 100% and sensitivity ranges from 50 to
100%, the analysis yields the unbiased response ratio of 2
regardless of the sensitivity (Fig. 1b).

When sensitivity is held at 100% and specificity ranges
from 50 to 100%, the response difference approaches the
truth linearly as the specificity approaches 100% (Fig. 2a).
In this situation, the response difference can be corrected by
dividing the observed response difference by the specificity,
which is then expected to equal the true response difference
[11]. In like fashion, when specificity is held at 100% and
sensitivity ranges from 50 to 100%, the response difference
approaches the truth linearly as the sensitivity approaches
100% (Fig. 2b). Here, the response difference can be cor-
rected by dividing the observed response difference by the
sensitivity to obtain the expected truth.

When sensitivity is held at 100% and specificity ranges
from 50 to 100%, the odd ratio approaches the truth some-
what linearly as the specificity approaches 100% (Fig. 3a).
In contrast, when specificity is held at 100% and sensitivity
ranges from 50 to 100%, the odds ratio is further from the
truth and exponentially approaches the truth as sensitivity
approaches 100% (Fig. 3b).

Two Case Studies from a Clinical Trial

As an illustration of the methodology, a post hoc analysis
was undertaken on data from a randomized, double-blind,
placebo-controlled, flexible-dose, sildenafil citrate (Viagra)
trial in which men were randomized to receive sildenafil
or placebo for 12 weeks [12]. This trial was conducted in
accordance with Good Clinical Practice Guidelines and the
Declaration of Helsinki, and was approved by local institu-
tional review boards. All subjects provided written informed
consent before enrollment.

From this clinical trial, two illustrative examples of post
hoc responder analyses were performed on the six-item erec-
tile function domain of the International Index of Erectile
Function (IIEF; range: 1–30, higher scores are better), a PRO
measure [13, 14]. Measures of effect included the response
ratio, response difference, and odds ratio. For each measure
of effect, the uncorrected (original) and corrected (adjusted)
data were calculated using StatXact™ 11.1.0.

Example 1: Erectile Function Domain Scores at Week
12

Based on a previous validation study, a cutoff score of 25
on the erectile function domain of the IIEF was determined
to separate men classified as having normal erectile func-
tion (scores from 26 to 30 inclusive) versus men having less
than normal erectile functioning (scores from 1 to 25 inclu-
sive), which includes mild or more severe forms; the sen-
sitivity and specificity of the IIEF erectile function domain
were 0.97 and 0.88, respectively [15, 16]. Of interest here
is the relationship between treatment groups (sildenafil vs.
placebo) and whether or not normal erectile function was
achieved at week 12 based on the erectile function domain
of the IIEF (responder with a score from 26 to 30 versus
non-responder otherwise).
It should be noted that successful treatment can be defined in different ways and can still be achieved without reaching as high a hurdle as normal erectile functioning at week 12. Other metrics for successful treatment, which do not require complete transition to normal erectile functioning, include to change favorably by at least a minimum amount, as illustrated next.

**Example 2: Change in Erectile Function Domain Scores at Week 12**

Based on another validation study, at least a 4-point improvement was determined to be the “minimal clinically important difference” on the erectile function domain of the IIEF; the corresponding sensitivity and specificity values were 0.74 and 0.73, respectively [17]. In our example, an individual increase of at least four points on the erectile function domain from baseline to week 12 was considered as clinically meaningful within-patient improvement. Of interest here is the relationship between treatment groups (sildenafil vs. placebo) and whether or not an increase of at least four points was achieved on the change score of the erectile function domain (yes, for responder versus no, for non-responders).
Results

Example 1

Table 5 shows the unadjusted data of response by treatment where a responder is classified as having had a normal erectile function, defined as a score on the erectile function domain above 25 (26 to 30) at week 12. The unadjusted proportion who responded with sildenafil was 0.48 (= 54/112), while the unadjusted proportion who responded with placebo was 0.14 (= 16/115). Given sensitivity and specificity of response equal to 0.97 and 0.88, respectively, Table 5 also shows the corresponding corrected or adjusted data of response by treatment. The adjusted proportion who responded with sildenafil was 0.43 (= 47.7/112), while the adjusted proportion who responded with placebo was 0.02 (= 2.6/115).

Based on Table 5, a comparison can be made between the unadjusted and adjusted results in terms of three metrics of treatment effects: response ratio, response difference, and odds ratio. The adjusted results indicated a much larger effect of active treatment for all three metrics; in this particular case, the unadjusted results underestimated the treatment effect. The estimated adjusted response ratio of 18.84 was much higher than the estimated unadjusted response ratio of 3.47 (95% confidence interval, CI: 2.15 to 5.71) and not even within the latter’s 95% CI. The estimated adjusted odds ratio of 32.07 was considerably much higher than the estimated odds ratio of 5.76 (95% CI: 3.02 to 10.98) and not even within 95% CI for the unadjusted odds ratio.

Fig. 3  a. Odds Ratio vs. Specificity (Sensitivity = 1). b. Odds Ratio vs. Sensitivity (Specificity = 1)
While the adjusted response difference of 0.41 is within the 95% confidence interval for the unadjusted response difference of 0.34 (95% CI 0.23 to 0.45), which does not necessarily imply lack of a statistical significance between the adjusted and unadjusted values, the difference between the two response differences of 0.07 (= 0.41–0.34) is noticeable (approximately one-fifth of the unadjusted response difference). In fact, if the adjusted proportion of 0.41 is taken as the fixed population proportion, a one-sample test for a proportion would give a statistically significant difference at the 0.05 level of significance between the adjusted and unadjusted response difference \([Z = 0.07/square root of [(0.41)(0.59)/227]] = 0.07/0.033 = 2.14 > 1.96]\).

**Example 2**

Table 6 shows the unadjusted data of response by treatment where a responder is classified as having had at least a four-point increase or improvement in the erectile function domain from baseline to week 12. The unadjusted proportion who responded with sildenafil was 0.76 (= 85/112), while the unadjusted proportion who responded with placebo was 0.41 (= 47/115). Given sensitivity and specificity of response equal to 0.74 and 0.73, respectively, Table 6 (second cell entry) also shows the corresponding corrected (adjusted) data of response by treatment. Therefore, within-patient change is effectively determined by adjusting patient counts using the original responder threshold and diagnostic criteria (sensitivity and specificity), without adjusting the threshold itself.

But this table includes an expected corrected cell count that is negative, which is not permissible. What happened? When sensitivity < \(a/(a + c)\), as is the case here \([0.74 < 85/(85 + 27) = 0.76]\), the corrected value for \(C\) becomes negative. An alternative approach is to choose the closest permissible value to the observed sensitivity so that this revised value of specificity equals \([a/(a + c)] = 85/(85 + 27) = 0.76\) instead of 0.74, with no change in specificity (0.73). Table 6 provides the revised corrected data of response by treatment. The revised adjusted proportion who responded with sildenafil became 0.998 (= 111.8/112), while the revised adjusted proportion who responded with placebo became 0.283 (= 32.6/115).

Based on Table 6, a comparison can be made between the unadjusted and (revised) adjusted results in terms of three metrics of treatment effects: response ratio, response difference, and odds ratio. The adjusted results indicated a much larger effect of treatment for all three metrics; in this particular case, the unadjusted results underestimated the treatment effect. The estimated adjusted response ratio of 3.53 was much higher than the estimated unadjusted response ratio of 1.86 (95% CI 1.47–2.39) and not within the 95% CI for the unadjusted response ratio. The estimated adjusted odds ratio of 1412.93 was vastly much higher than the estimated odds ratio of 4.56 (95% CI 2.57–8.06) and nowhere near the 95% CI for the unadjusted odds ratio. Moreover, the estimated adjusted response difference of 0.72 was twice as high as the estimated unadjusted response difference of 0.35 (95% CI 0.23–0.47) and not within the 95% CI for the unadjusted response ratio.
Discussion

Anchor-Based Methodology

Patient-reported measures, like all measurement instruments, are not perfectly reliable owing to measurement error [18, 19]. As subjective assessments, PRO measurement requires a series of judicious checks and balances.

Consider the context of change scores on a PRO measure to define a responder after treatment intervention. The concern here is that some individuals may be classified as responders (based on the cutoff or threshold score on the targeted PRO measure of interest) when in fact they have not changed according to an external indicator of true change taken as the “gold standard”; these individuals exhibit false-positive (observed) changes. Similarly, some individuals may be classified as non-responders (again based on the same cutoff or threshold score on the targeted PRO measure) when in fact they truly have changed according to the same external criterion; these individuals exhibit false-negative changes. The external criterion, which serves as the gold standard, is referred in the literature as an anchor measure, and relate changes on the PRO instrument to this criterion. Anchor-based methods use the anchor criterion to determine what patients consider to be a presumably true meaningful change in their condition [3, 9, 19–22].

Therefore, selecting the appropriate anchor measure(s) is of prime importance, as is the method for linking the anchor measure to the targeted PRO measure. The anchor indicator should be plainly understood in context, be easier to interpret than the PRO measure itself, and be sufficiently correlated to the targeted PRO measure. Anchor-based methods anchor the anchor criterion to determine what patients consider to be a presumably true meaningful change in their condition and relate changes on the PRO instrument to this criterion.

Anchor-based methodology is used to determine sensitivity and specificity [1, 3, 9, 19–23], and the two IIEF examples featured in the manuscript, only when the instrument’s sensitivity and specificity are each equal to 1 with respect to the external anchor criterion is there no classification or responder bias, with no calibration or adjustment needed.

For the example given on change in EF domain scores at week 12 (Example 1), sensitivity and specificity were obtained from previous validation research [15] where the anchor criterion was whether the patient had established clinical diagnosis of erectile dysfunction (ED). This dichotomy (yes, no) was regressed on the EF domain score, the targeted PRO measure of interest, in a logistic regression model and, using ROC curve analysis, the optimal cutoff score on the EF domain was selected essentially to maximize the average of sensitivity and specificity. Sensitivity and specificity were 0.97 and 0.88, respectively.

For the example given on change in EF domain scores at week 12 (Example 2), sensitivity and specificity were obtained from previous validation research [17] where the anchor was patient-reported level of satisfaction with sexual intercourse, also from the IIEF, selected because of its relevance to the US National Institutes of Health definition of ED and its grounding in prior psychometric research. Change scores, from baseline to week 12, on the satisfaction item were dichotomized into improvement or no improvement. This dichotomy was regressed on the change score of the EF domain, the targeted PRO measure of interest, in a logistic regression model and, using ROC curve analysis, the optimal cutoff on the change score of EF domain was selected based to maximize the sum of sensitivity and
specificity (i.e., where most patients are correctly classified by the cutoff change score on the IIEF EF domain as having improved versus not having improved). Sensitivity and specificity were 0.74 and 0.73, respectively.

For subjective measures in general, the FDA recommends (also supported by the medical literature) three types of anchors, as external criteria approximating truth, to generate appropriate thresholds for meaningful within-patient change: (1) static, current-state global impression of severity scale (e.g., patient global impression of severity); (2) global impression of change scale (e.g., patient global impression of change); and (3) well-established clinical outcomes (if relevant) [24].

**Responder Analysis in Perspective**

Responder analysis is of course not a new subject. Nor is adjustment for misclassification (information) bias or measurement error on exposure status or disease status or both. But the fusion of the two topics is novel in the context of clinical outcome assessments in general and PRO measures in particular. In this manuscript, correction formulas for misclassification bias on binary disease status (yes, no) are translated and used to correct for misclassification of binary responder status (yes, no) based on a PRO measure, with binary exposure status (experimental treatment, control treatment) assumed to be measured perfectly. In a well-conducted randomized controlled trial the assumption of no misclassification in treatment status is quite reasonable.

The methodology in this paper centered on patient-reported measures as the focus point but is general enough to also apply to other types of clinical outcome assessments [25, 26] including clinician-reported outcome measures, observer-reported outcome measures, and performance outcome measures, as well as other outcomes beyond traditional disease status. Moreover, the methodology is applicable across therapeutic areas, extending beyond urology (featured in this article) and including (but not limited to) oncology where PROs have a major role in patient progression (where being a responder is an unfavorable rather than favorable outcome).

The value of enhancing interpretation of PRO measures using a responder definition based on meaningful within-person change, which naturally and inevitably leads to a comparison of responder rates (proportions) between treatment groups, has been discussed [1, 4]. Such a dichotomy serves as a practical, comprehensible way to distill complicated phenomena into simple categories [27]. Stakeholders of health can understand percent or proportion of success between treatment groups (such as a difference in proportions) as an intuitive, understandable metric of treatment benefit.

It should be emphasized, however, that the main analysis of patient-reported measures with quantitative (ordinal or continuous) data should be analyzed as such, rather than a dichotomized version of them, in order to preserve the full information and natural structure inherent in the original data [5, 24]. This article, therefore, does not advocate that the original metric of a quantitative PRO measure be replaced with a discretized version of it for the main analysis. On the contrary, for a PRO variable analyzed as continuous, the primary metric for treatment effect should be the difference in mean scores, or in mean change in baseline, emanating from a regression or longitudinal model for continuous data.

For instance, consider Example 2 on a responder analysis involving at least a four-point improvement from baseline on the erectile function domain scores at week 12. Its main analysis from an analysis of covariance model was prospectively based on the mean change from baseline between the sildenafil group [9.3 points; 95% confidence interval (CI), 7.9–10.7] and the placebo group (3.6 points; 95% CI 2.2–5.0) [12], which can be augmented by the results of the retrospective responder analysis presented and interpreted in this current paper. This difference of 5.7 points (95% CI 3.8–7.6; p-value < 0.001) is compatible or consonant with an adjusted response difference and ratio of 0.72 and 3.53, respectively (based on a response proportion of 0.998 from placebo minus response proportion of 0.283 from placebo). Thus, responder analysis is intended to supplement, not replace, such a main analysis for the purpose of advancing interpretation of a quantitative PRO measure above and beyond its primary analysis and interpretation from original data using a type of regression model [7, 8].

As long as the analytic plan for statistical inference for a quantitative PRO measure is pre-specified in the right order, with the analysis of means superseding the analysis of proportions, the interpretation of treatment effect using difference in mean scores and in responder proportions are not mutually exclusive. Both metrics of treatment effect can be complementary, coexisting synergistically, with the difference in responder proportion serving as an interpretive aid to augment the primary analysis based on difference in mean scores.

**Misclassification Issues**

The same set of conclusions made about non-differential (and differential) disease misclassification in this article also apply to non-differential (and differential) responder misclassification, as the latter is a variant of the former. Non-differential responder misclassification occurs when the proportion of subjects misclassified on responder status does not depend on the status of the subject with respect to treatment status (or any other variables that might be in
the analysis). Bias introduced by non-differential misclassification of a binary response, which like that of binary disease status of which it is variant, is predictable in being bias toward the null value of no treatment effect (provided that the misclassification is independent of other errors), as it is also for non-differential misclassification of a binary exposure status (like treatment) [28, 29]. Therefore, the clear underestimation of treatment effect (as measured by the response difference, response ratio, and odds ratio) in the two case studies is expected. By extension, as is the case for simultaneous (joint) misclassification of exposure and disease [29, 30], non-differential joint misclassification of both treatment and response will also generally result in bias toward the null (provided no misclassification of covariates that might be presented in the analysis), if misclassification of dichotomous treatment is independent of dichotomous response status.

It should be noted, though, that non-differentially alone does not guarantee bias toward the null. While non-differential misclassification in most situations is expected or predicted to result in bias toward the null, non-differential response (or treatment) classification can at times produce bias away from the null if the response (or treatment) variable has more than two levels or if the classification errors depend on errors from other variables, as would also be the case more generally for exposure or disease misclassification [29, 30]. In contrast, differential misclassification of response status (like differential disease or exposure classification) causes unpredictable bias in the response difference, response ratio, or odd ratio that is either towards or away from the null, depending on the proportions of subjects misclassified [10, 11, 28, 29].

Misclassification of responders and non-responders stems from the imperfection of the PRO measure owing to multiple factors that may bias patients’ responses [31]. This article focuses on addressing bias for responder misclassification under the assumption of no treatment misclassification when there are two levels of responder status (yes, no) and of treatment status (experimental, control). In general, if errors in detecting the presence of a responder are equal between experimental treatment and control treatment (with sensitivity less than 100%), but no errors are made in the classification of non-responders (i.e., specificity is 100%), then the response ratio will not be biased but the odds ratio and risk difference will be biased towards the null value of no effect. If no errors are made in detecting the presence of a responder (i.e., 100% sensitivity), but equal errors are made among treatment and comparison groups in the classification of non-responders (with specificity less than 100%), then response ratio, odds ratio and response difference will be biased toward the null.

As stated and illustrated in this article, when there is no misclassification of treatment, a limitation of the formulas intended to correct for non-differential misclassification of binary responder status may yield negative and hence inappropriate results for the corrected cell frequencies. Following from the same set of circumstances and limitations as correcting for non-differential misclassification of binary disease status [10], adjusting for non-differential misclassification of binary responder status gives a negative corrected count in any one of five situations [where sensitivity (SE) and specificity (SP) are for misclassification of responder status]: (1) SE + SP = 1; (2) SP < c/(a + c), giving a negative corrected value for A; 3) SP < d/(b + d), giving a negative corrected value for B; (4) SE < a/(a + c), giving a negative corrected value for C (which was found in the second example); and (5) SE < b/(b + d), giving a negative corrected value for D. Although not a perfect solution, one viable way to address this problem is to select the closest alternative value to SE or SP that changes a cell count from negative to positive, as was performed in the second example. Further research is encouraged to investigate negative cell counts and how to best address them.

The simple bias-correction analysis introduced here for responder analysis of PRO measures is an improvement over its conventional counterpart, which implicitly assumes no misclassification error at all on responder status (100% sensitivity and 100% specificity). But this simple bias-correcting implies that the diagnostic parameters (i.e., sensitivity and specificity) are fixed and known without error, a situation that is rarely realized. For example, there is no bona fide gold standard of measurement for responder status; the chosen anchor measure may be suitable approximation for true responder status but not a perfect, error-free indicator of it. Thus there is expected uncertainty in the sensitivity and specificity rates themselves. This limitation is not restricted to PRO measures but applies generally to many exposure and outcome variables in epidemiology [11].

During the validation stage of quantifying misclassification rates for responder status, the use and concordance of multiple anchor measures is one way to mitigate the lack of an undisputed gold standard of responder status. As with the case of epidemiologic outcomes, responder status for PRO measures can extend beyond the simple bias-correction analysis to, for instance, multidimensional bias analysis (where the methods for simple bias-correction analysis are repeated with a plausible range of values for sensitivity and specificity) and probabilistic bias analysis (where probability distributions are assigned to sensitivity and specificity that, after Monte Carlo sampling techniques, generate a frequency distribution of correct estimates of effect) [11], which can also allow for differential misclassification of responder status between treatments. While these more advanced methods are beyond the scope of this article, they deserve attention for addressing responder analysis of PRO measures. In addition, cumulative distribution functions, one
for each treatment group, can be used to evaluate a range of responder cutoffs on a PRO measure and thereby assess the robustness of the chosen cutoff [1, 3, 4].

One area of research on misclassification issues involves expanding classification from a dichotomy of response (responder, no responder) to a trichotomy (improvement, stable, deterioration) and correcting for misclassification bias. These more discriminating responder categorizations in a longitudinal study are expected to be more sensitive and discerning than a simple responder dichotomy in reflecting the main analysis on the original continuous scale of an instrument. In oncology, for instance, such a candidate instrument for three-level responder adjustment includes the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire that has been analyzed longitudinally based on its original metric in the primary analysis and also to classify subjects with at least a 10-point improvement, at least 10-point deterioration, and otherwise no real change (stable) in secondary analyses [32].

**Conclusion**

In summary, quantitative PRO measures ideally are analyzed on their original metric in the primary analysis and, as a way to convey meaning and understanding of PRO scores, responder analyses are often used in a secondary analysis to complement the interpretation of those primary analyses. Thus, a useful way to lend meaning and interpretation to a quantitative PRO measure is to dichotomize between values where within-patient changes are considered clinically important and those that are not. Nonetheless, a PRO scale with a cutoff score that discriminates well between responders and non-responders is still typically fraught with misclassification of responder status, at least to a certain extent, while there is usually no treatment misclassification in a well-conducted study.

The methodology in this article can be applied to different therapeutic areas and different types of clinical outcome assessments. In the context of PRO measures, this article provides formulas that correct for responder misclassification under the assumption of no treatment misclassification and illustrates the methodology with two case studies from sexual medicine. As such, treatment effect bias from misclassification of responder status on PRO measures is addressed and corrected, leading to more trustworthy interpretation and effective decision-making.

**Author Contributions**

JC and RC: Substantial contributions to the conception or design of the work; the acquisition, analysis, or interpretation of the data for the work; Drafting of work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Data Availability**

Upon request, and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

**Declaration**

**Conflict of interest**

The authors are employees and stockholders of Pfizer Inc. This study was sponsored by Pfizer.

**Open Access**

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. FDA (Food and Drug Administration). Guidance for industry - Patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, Maryland: U.S. Department of Health and Human Services; 2009.
2. Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton: Chapman & Hall/CRC Press; 2013.

3. Cappelleri JC, Bushmakin AG. Interpretation of patient-reported outcomes. Stat Methods Med Res. 2014;23:460–83.

4. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163–9.

5. EMA (European Medicines Agency). Guideline on multiplicity issues in clinical trials. London: European Medicines Agency; 2017.

6. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of change in chronic pain intensity measured on an 11-point numerical rating scale. Pain. 2001;94:149–58.

7. Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials. 2007;8:31.

8. Uryniak T, Chan ISF, Fedorov VV, Jiang Q, Oppenheimer L, Snapinn SM, et al. Responder analyses: a PhRMA position paper. Stat Biopharm Res. 2011;3:476–87.

9. Revicki D, Hays R, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102–9.

10. Kleinbaum DG, Sullivan KM, Barker NB. ActiVepi companion textbook: a supplement for use with the ActiVepi CD-ROM. 2nd ed. New York: Springer; 2013.

11. Lash TL, Fox MP, Fink AK. Applying quantitative bias analyses to epidemiologic data. New York: Springer; 2009.

12. O‘Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S. On behalf of the US SEAR Study Group. Self-esteem, confidence, and relationship satisfaction in men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study in the United States. J Urol. 2006;175:1058–62.

13. Rosen RC, Cappelleri JC, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.

14. Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.

15. Cappelleri JC, Rosen RC, Smith MD, Quirk F, Maytom MC, Mishra A, et al. Some developments on the International Index of Erectile Function (IIEF). Drug Inf J. 1999;33:179–90.

16. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54:346–51.

17. Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function Scale. Eur Urol. 2011;60:1010–6.

18. Fayers FM, Machin D. Quality of life: the Assessment, analysis and reporting of patient-reported outcomes. 3rd ed. Chichester: Wiley; 2016.

19. King MT, Dueck AC, Revicki DA. Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management. Med Care. 2019;57:S38–45.

20. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395–407.

21. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in medicine: a practical guide. New York: Cambridge University Press; 2011.

22. King MT. A point of minimal important difference (MID): A critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:171–84.

23. Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res. 2018;2018(27):33–40.

24. FDA (Food and Drug Administration). Patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making: draft guidance documents; 2019 https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. (Accessed October 27, 2020.)

25. Cappelleri JC, Spielberg SP. Advances in clinical outcome assessments. Therapeutic Innovat Regul Sci. 2015;49:780–2.

26. FDA (Food and Drug Administration). Clinical outcome assessment (COA) compendium. Silver Spring, Maryland: U.S. Department of Health and Human Services; 2019.

27. Lewis JA. In defence of the dichotomy. Pharm Stat. 2004;3:77–9.

28. Chen Q, Galfalvy H, Duan N. Effects of disease misclassification of exposure and disease on epidemiologic measures of association. J Clin Epidemiol. 1993;46:1195–202.

29. Chang EM, Gillespie EF, Shaverdian N. Truthfulness in patient-reported outcomes: factors affecting patients’ responses and impact on data quality. Patient Relat Outcome Measures. 2019;10:171–86.

30. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.